NEUTROLIS

neutrolis-logo

Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs). NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases. Although NETs represent one of the most important immunology discoveries in the past 20 years, there is no therapy on the market that effectively targets and removes NETs. Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and s... upported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that effectively removes NETs and halt their pathologic effects on end-organs. Neutrolis has a strong patent portfolio for new molecular entity and method of use. The lead molecule, NTR-441, is slated to enter clinical trials in 2021.

#SimilarOrganizations #People #Financial #Website #More

NEUTROLIS

Social Links:

Industry:
Biotechnology Life Science Medical

Founded:
2017-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.neutrolis.com

Total Employee:
1+

Status:
Active

Total Funding:
23.14 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Apache Wordpress Plugins Sitelinks Search Box Organization Schema


Similar Organizations

aulos-bioscience-logo

Aulos Bioscience

Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.

imago-biosciences-logo

Imago BioSciences

Imago is a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs).

juventas-therapeutics-logo

Juventas Therapeutics

Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.

third-harmonic-bio-logo

Third Harmonic Bio

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.

Current Employees Featured

john-sundy_image

John Sundy
John Sundy Board Of Directors @ Neutrolis
Board Of Directors
2022-01-01

abdul-hakkim_image

Abdul Hakkim
Abdul Hakkim Co-Founder, Co-President, and COO @ Neutrolis
Co-Founder, Co-President, and COO
2021-10-01

toby-fox_image

Toby Fox
Toby Fox Co-founder & CEO @ Neutrolis
Co-founder & CEO
2020-06-01

Founder


abdul-hakkim_image

Abdul Hakkim

toby-fox_image

Toby Fox

Investors List

prefix-capital_image

Prefix Capital

Prefix Capital investment in Venture Round - Neutrolis

Official Site Inspections

http://www.neutrolis.com Semrush global rank: 5.92 M Semrush visits lastest month: 1.39 K

  • Host name: aacb0a264e514dd48.awsglobalaccelerator.com
  • IP address: 99.83.190.102
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "Neutrolis"

Neutrolis

Neutrolis aims to transform patients' lives and revolutionize the treatment of autoimmune and inflammatory diseases by creating precision therapies to target NETs. Overactive neutrophils …See details»

About - Neutrolis

Neutrolis is a clinical stage company developing a robust pipeline of therapeutics in major disease areas driven by NET-based pathologies starting with lupus. Toby is co-founder, CEO, CSO …See details»

Neutrolis - Crunchbase Company Profile & Funding

Neutrolis was founded by two of the earliest and most cited leaders in the NETs field and supported by a seasoned biotech executive with a track record of successful M&A. The company’s pipeline includes NTR-441 and NTR-10, that …See details»

Patients - neutrolis.com

Neutrolis is the leading therapeutics company addressing neutrophil-based diseases starting with Neutrophil Extracellular Traps (NETs) and other sources of pathologic extracellular DNA. …See details»

Neutrolis Company Profile 2024: Valuation, Funding & Investors

Operator of a biotechnology company intended to develop therapeutics that target neutrophils, the most abundant immune cell in our body.See details»

Neutrolis Inc - LinkedIn

Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil Extracellular...See details»

Resident Company Q&A: Neutrolis - LabCentral | Cambridge, MA

Oct 26, 2021 · As we continue to highlight the groundbreaking work of LabCentral resident and alumni biotech companies, here’s a snapshot of Neutrolis, Inc., a preclinical-stage resident …See details»

Neutrolis - Funding, Financials, Valuation & Investors - Crunchbase

Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).See details»

Neutrolis - Contacts, Employees, Board Members, Advisors & Alumni

Neutrolis is a candidate-stage company advancing its first-in-class therapies that target Neutrophil Extracellular Traps (NETs).See details»

Neutrolis Inc: Contact Details and Business Profile

Neutrolis, Inc. is a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cell in our body. Neutrolis’ lead program targets Neutrophil …See details»

Neutrolis - Overview, News & Similar companies | ZoomInfo.com

Aug 3, 2020 · Neutrolis contact info: Phone number: (617) 863-3650 Website: www.neutrolis.com What does Neutrolis do? Neutrolis, Inc. is a biotechnology company developing therapeutics …See details»

Platform - Neutrolis

Neutrolis’ pioneering science, paired with powerful exDNASEâ„¢ design and manufacturing capabilities, underpins our unique therapeutics platform. Our proprietary exDNASEâ„¢ platform …See details»

Neutrolis - VentureRadar

Neutrolis aims to transform patients' lives and revolutionize the treatment of autoimmune and inflammatory diseases by creating precision therapies to target NETs. Neutrolis' platform …See details»

Neutrolis - Work in biotech

Neutrolis is a clinical-stage company focused on developing innovative therapies that target neutrophils, the most abundant immune cells in the body. Their research centers around …See details»

Neutrolis announces development of enzyme for severe COVID-19

Aug 7, 2020 · Neutrolis, a biotechnology company developing therapeutics that target neutrophils, has announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that …See details»

Contact - Neutrolis

Neutrolis is actively looking for collaborators of all types to help us achieve our broad company vision and drive patient impact. Please contact us. Get in touch!See details»

Neutrolis Announces Development Of First-In-Class Treatment …

Aug 3, 2020 · Neutrolis is a biotechnology company developing first-in-class therapies that target neutrophils and their pathogenic products, including NETs. Neutrolis' proprietary platform, …See details»

Neutrolis announces development of first-in-class therapy to …

Aug 5, 2020 · Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, …See details»

Pipeline - Neutrolis

Our pipeline of therapeutics is being developed to specifically target the causative pathological mechanisms of a number of NETs-based diseases and beyond. Neutrolis’ unique approach …See details»

Neutrolis Develops Treatment Targeting NETs for Patients with …

Aug 7, 2020 · Neutrolis announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular …See details»

linkstock.net © 2022. All rights reserved